After Hour Gainers / Losers

Top gainers, as of 5:15 p.m.: MFRM +6.8%. ULTA +6.1%. AMED +5.9%. EGY +5.4%. PCYC +4.7%.

Top losers, as of 5:15 p.m.: ARO -13.3%. RPTP -11.8%. MNKD -8.5%. ZGNX -7.9%. ZBB -6.9%.

From other sites
Comments (4)
  • oneotherfool
    , contributor
    Comments (495) | Send Message
    $MNKD is back up to the closing price. It was just one 5K trade. Lucky buyer!
    13 Mar 2014, 06:21 PM Reply Like
  • 3D Investing
    , contributor
    Comments (1552) | Send Message
    Probably mistyped the selling price or selected "buy" instead of "sell". I've done that a couple times.
    13 Mar 2014, 10:57 PM Reply Like
  • MorrisSean
    , contributor
    Comments (103) | Send Message
    Well if someone was trying to create an after hours panic, it doesn't seem to have worked. I agree, Lucky Buyer!
    13 Mar 2014, 09:04 PM Reply Like
  • Bentio Gonzalez
    , contributor
    Comments (26) | Send Message
    Are you kidding me? Did you listen to the management report online? The effort to compare Cystagon 100% dosing compliance with discontinuation of Procysbi? Those numbers are not even close to useful numbers. Well, at least we have an admission by RPTP management that 20% of the patients are discontinuing Procysbi who being therapy on it. Does anyone honestly believe more than 20% of patients discontinue Cystagon when failure to take the product would mean a slow, painful death?


    We also know that growth in patient sales of Procysbi is leveling off and any movement into the European market will not happen until at least April or May. Not mentioned was the real difficulty which is pricing which is unlikely to be anywhere near projections made earlier by Raptor management.


    We also know the Huntington's Disease results don't tell us much with regard to utility and the management is not proposing any timeline for FDA approval of RP-103 for Huntington's Disease. Probably best if 20% of the patients on the drug currently quit taking it because they can't tolerate it and they need it to stay alive. RP-103 will not stop Huntington's Disease, only at best allay some of its symptoms. If the end result is the same, how many patients do you really believe would be lining up to take this drug? Not many I suspect.
    14 Mar 2014, 09:34 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs